
CLAIMS


1. A compound of formula (I) which is 2-[(4*S*)-6-(4-Chlorophenyl)-1-methyl-8-(methyloxy)-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepin-4-yl]-*N*-ethylacetamide



(I)

or a salt thereof.


2. A compound of formula (I) which is 2-[(4*S*)-6-(4-Chlorophenyl)-1-methyl-8-(methyloxy)-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepin-4-yl]-*N*-ethylacetamide



(I)

or a pharmaceutically acceptable salt thereof.

3. A compound of formula (I) which is 2-[(4*S*)-6-(4-Chlorophenyl)-1-methyl-8-(methyloxy)-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepin-4-yl]-*N*-ethylacetamide



(I)

4. A pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 2 and one or more pharmaceutically acceptable carriers, diluents or excipients.

5. A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 3 and one or more pharmaceutically acceptable carriers, diluents or excipients.

6. A combination pharmaceutical product comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 2 together with one or more other therapeutically active agents.

7. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 2 for use in therapy.

8. A compound of formula (I) as defined in claim 3 for use in therapy.

9. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 2, for use in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

10. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use according to claim 9, wherein the disease or condition is a chronic autoimmune and/or inflammatory condition.

11. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use according to claim 9, wherein the disease or condition is cancer.

12. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 2, in the manufacture of a medicament for the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

13. A use of claim 12, wherein a therapeutically

effective amount of said medicament is to be administered to a subject in need thereof.

14. A according to claim 12, wherein the disease or condition is a chronic autoimmune and/or inflammatory condition.


15. A use according to claim 12, wherein the disease or condition is cancer.

16. A use according to any one of claims 13 to 15, wherein the subject is a human.

17. A use according to any one of claims 12 to 16, wherein said medicament is to be contacted with the bromodomain.

CLAIMS


1. A compound of formula (I) which is 2-[(4*S*)-6-(4-Chlorophenyl)-1-methyl-8-(methyloxy)-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepin-4-yl]-*N*-ethylacetamide



(I)

or a pharmaceutically acceptable salt thereof.

2. A compound of formula (I) which is 2-[(4*S*)-6-(4-Chlorophenyl)-1-methyl-8-(methyloxy)-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepin-4-yl]-*N*-ethylacetamide



(I)

3. A pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 and one or more pharmaceutically acceptable carriers, diluents or excipients.

4. A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 2 and one or more pharmaceutically acceptable carriers, diluents or excipients.

5. A combination pharmaceutical product comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 together with one or more other therapeutically active agents.

6. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 for use in therapy.

7. A compound of formula (I) as defined in claim 2 for use in therapy.

8. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 for use in the treatment of a chronic autoimmune and/or inflammatory condition.

9. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 for use in the treatment of cancer.

10. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1, in the manufacture of a medicament for the treatment of a chronic autoimmune and/or inflammatory condition.

11. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1, in the manufacture of a medicament for the treatment of cancer.

12. A use according to claim 11 wherein the cancer is selected from hematological, epithelial including lung, breast and colon carcinomas, midline carcinomas, mesenchymal, hepatic, renal and neurological tumours.

13. A use according to claim 13 in which the haematological cancer is leukaemia.